The Pharma Data

JANUARY 31, 2021

We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. . TOKYO and CAMBRIDGE, England , Feb. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. SOURCE Sosei Heptares.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs Disease 52

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. . TOKYO and CAMBRIDGE, England , Nov. SOURCE Sosei Heptares.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

DECEMBER 21, 2020

A further aim of the collaboration is to generate high resolution structural information around the GPCR-E3 ligase complex to enhance drug discovery efforts as well as provide proof of concept for targeted degradation discovery approaches with other GPCRs and other target classes. View original content: [link]. Source link.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40